Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 5
Submit an article Journal homepage
133
Views
1
CrossRef citations to date
0
Altmetric
Review

The pharmacoeconomics of managing acute agitation in the emergency department: what do we know and how do we approach it?

Esther W Chan Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2/F Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong; Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2/F Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong
,
David McD Taylor Emergency Department, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia; Emergency Department, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia
,
Jonathan C Knott Emergency Department, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia; Emergency Department, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia
,
Danny Liew Melbourne EpiCentre (Centre for Clinical Epidemiology, Biostatistics and Health Services Research), The University of Melbourne and Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia; Melbourne EpiCentre (Centre for Clinical Epidemiology, Biostatistics and Health Services Research), The University of Melbourne and Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia
&
David CM Kong Centre for Medicine Use and Safety, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. [email protected]; Centre for Medicine Use and Safety, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. [email protected]
Pages 589-595 | Published online: 09 Jan 2014

References

  • Downey LV, Zun LS, Gonzales SJ. Frequency of alternative to restraints and seclusion and uses of agitation reduction techniques in the emergency department. Gen. Hosp. Psychiatry 29(6), 470–474 (2007).
  • Allen MH. Acute care of the agitated psychotic patient. J. Clin. Psychiatry. 61(Suppl. 14), 1–55 (2000).
  • Chan EW, Taylor DM, Knott JC, Kong DC. Variation in the management of hypothetical cases of acute agitation in Australasian emergency departments. Emerg. Med. Australas. 23(1), 23–32 (2011).
  • Hoch JS, Dewa CS. Lessons from trial-based cost–effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics 25(10), 807–816 (2007).
  • Hill S, Petit J. The violent patient. Emerg. Med. Clin. North Am. 18(2), 301–15 (2000).
  • Chan EW, Knott JC, Liew D, Taylor DMcD, Knott JC, Kong DCM. Cost-minimisation analysis of midazolam versus droperidol in the management of acute agitation in the emergency department. J. Pharm. Prac. Res. 42(1), 11–16 (2012).
  • Jerrell JM. Cost–effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr. Bull. 28(4), 589–605 (2002).
  • Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol. Bull. 32(4), 721–729 (1996).
  • Bellnier TJ. Continuum of care: stabilizing the acutely agitated patient. Am. J. Health. Syst. Pharm. 59(17 Suppl. 5), S12–S18 (2002).
  • MacIntyre CR, Sindhusake D, Rubin G. Modelling strategies for reducing pharmaceutical costs in hospital. Int. J. Qual. Health Care 13(1), 63–69 (2001).
  • Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry 158(7), 1149–1151 (2001).
  • Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics 15(5), 469–480 (1999).
  • Freeman DJ, DiPaula BA, Love RC. Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study. Pharmacotherapy 29(8), 930–936 (2009).
  • Rosenheck R, Perlick D, Bingham S et al. Department of Veterans Affairs Cooperative Study Group on the Cost–effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290(20), 2693–2702 (2003).
  • Rosenheck RA, Leslie DL, Sindelar JL et al. Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) investigators. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch. Gen. Psychiatry 64(11), 1259–1268 (2007).
  • Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and functioning as a cost–effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J. Clin. Psychiatry 60(Suppl. 19), 38–45; discussion 46 (1999).
  • MacLaren R, Sullivan PW. Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients. Pharmacotherapy 25(10), 1319–1328 (2005).
  • Dasta JF, Kane-Gill SL, Pencina M et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. Crit. Care Med. 38(2), 497–503 (2010).
  • Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost–effectiveness analyses of antipsychotic use. Am. J. Psychiatry 163(12), 2047–2056 (2006).
  • Liu GG, Sun SX, Christensen DB, Luo X. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann. Pharmacother. 38(1), 134–141 (2004).
  • Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18(13), 877–893 (2004).
  • Peiró S, Gómez G, Navarro M, Guadarrama I, Rejas J; Psychosp Group. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Description and associated factors. The Psychosp study. Soc. Psychiatry Psychiatr. Epidemiol. 39(7), 507–513 (2004).
  • Damsa C, Hummel C, Sar V et al. Economic impact of crisis intervention in emergency psychiatry: a naturalistic study. Eur. Psychiatry 20(8), 562–566 (2005).
  • Elliott R, Payne K. Essentials of Economic Evaluation in Healthcare. Pharmaceutical Press, London, UK (2005).
  • Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (Third Edition). Oxford University Press, NY, USA (2005).
  • Rychlik R. Strategies in pharmacoeconomics and outcomes research. The Haworth Press, New York, USA (2002).
  • Singh B, Hawthorne G, Vos T. The role of economic evaluation in mental health care. Aust. N. Z. J. Psychiatry 35(1), 104–117 (2001).
  • Knapp M. Pharmacoeconomic evaluation and psychiatry. In: Pharmacoeconomics in Psychiatry. Taylor D, Knapp M, Kerwin R (Eds). Martin Dunitz, London, UK, 1–6 (2002).
  • Knapp M, Windmeijer F, Brown J et al.; SOHO Study Group. Cost–utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics 26(4), 341–358 (2008).
  • Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann. Emerg. Med. 47(1), 61–67 (2006).
  • Chan EW, Knott JC, Liew D, Taylor DMcD, Kong DCM. Pharmacoeconomic evaluation of midazolam versus droperidol in the management of acute agitation in the Emergency Department. Presented at: Asian Conference for Emergency Medicine, Bangkok, Thailand, July 2011 (poster presentation).
  • Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann. Emerg. Med. 56(4), 392–401.e1 (2010).
  • Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 15(7), 677–687 (2006).
  • Fein R. Economics of Mental Health. Basic Books, NY, USA (1958).
  • Briggs AH. Handling uncertainty in cost–effectiveness models. Pharmacoeconomics 17(5), 479–500 (2000).
  • Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319(7210), 635–638 (1999).
  • O’Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. Health Econ. 16(10), 1009–1023 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.